SRRK

Company Overview — What Does Scholar Rock Holding Corp Do?

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. Scholar Rock Holding Corp (SRRK) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jay T. Backstrom and employs approximately 140 people. With a market capitalization of $5.7B, SRRK is one of the notable companies in the Healthcare sector.

Scholar Rock Holding Corp (SRRK) Stock Rating — Hold (April 2026)

As of April 2026, Scholar Rock Holding Corp receives a Hold rating with a composite score of 35.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.SRRK ranks #1,694 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Scholar Rock Holding Corp ranks #160 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SRRK Stock Price and 52-Week Range

Scholar Rock Holding Corp (SRRK) currently trades at $50.50. The stock gained $1.31 (2.7%) in the most recent trading session. The 52-week high for SRRK is $49.82, which means the stock is currently trading 1.4% from its annual peak. The 52-week low is $22.71, putting the stock 122.4% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is SRRK Overvalued or Undervalued? — Valuation Analysis

Scholar Rock Holding Corp (SRRK) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 23.35x, versus the sector average of 2.75x.

At current multiples, Scholar Rock Holding Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Scholar Rock Holding Corp Profitability — ROE, Margins, and Quality Score

Scholar Rock Holding Corp (SRRK) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -143.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -86.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SRRK Debt, Balance Sheet, and Financial Health

Scholar Rock Holding Corp has a debt-to-equity ratio of 65.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 6.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $100M. Cash and equivalents stand at $287M.

SRRK has a beta of 1.38, meaning it is more volatile than the broader market — a $10,000 investment in SRRK would be expected to move 38.4% more than the S&P 500 on any given day. The stability factor score for Scholar Rock Holding Corp is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Scholar Rock Holding Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Scholar Rock Holding Corp reported revenue of $0 and earnings per share (EPS) of $-3.29. Net income for the quarter was $-351M. Operating income came in at $-358M.

In FY 2025, Scholar Rock Holding Corp reported revenue of $0 and earnings per share (EPS) of $-3.29. Net income for the quarter was $-378M. Operating income came in at $-385M.

In Q3 2025, Scholar Rock Holding Corp reported revenue of $0 and earnings per share (EPS) of $-0.90. Net income for the quarter was $-102M. Operating income came in at $-104M.

In Q2 2025, Scholar Rock Holding Corp reported revenue of $0 and earnings per share (EPS) of $-0.98. Net income for the quarter was $-110M. Operating income came in at $-112M.

Over the past 8 quarters, Scholar Rock Holding Corp has experienced revenue contraction from $0 to $0. Investors analyzing SRRK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SRRK Dividend Yield and Income Analysis

Scholar Rock Holding Corp (SRRK) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SRRK Momentum and Technical Analysis Profile

Scholar Rock Holding Corp (SRRK) has a momentum factor score of 62/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

SRRK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Scholar Rock Holding Corp (SRRK) ranks #160 out of 838 stocks based on the Blank Capital composite score. This places SRRK in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SRRK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SRRK vs S&P 500 (SPY) comparison to assess how Scholar Rock Holding Corp stacks up against the broader market across all factor dimensions.

SRRK Next Earnings Date

No upcoming earnings date has been announced for Scholar Rock Holding Corp (SRRK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SRRK? — Investment Thesis Summary

Scholar Rock Holding Corp presents a balanced picture with arguments on both sides. The quality score of 17/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. Price momentum is positive at 62/100, suggesting the trend favors buyers. High volatility (stability score 33/100) increases portfolio risk.

In summary, Scholar Rock Holding Corp (SRRK) earns a Hold rating with a composite score of 35.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SRRK stock.

Related Resources for SRRK Investors

Explore more research and tools: SRRK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SRRK head-to-head with peers: SRRK vs AZN, SRRK vs SLGL, SRRK vs VMD.